BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30586199)

  • 1. Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine-induced bronchoconstriction: A noninferiority study using metered dose vs. dry powder inhaler.
    Singh D; van den Berg F; Leaker B; Corradi M; Jabbal S; Collarini S; Mongelli V; Santoro L; Piccinno A; Biondaro S; Lipworth B
    Br J Clin Pharmacol; 2019 Apr; 85(4):729-736. PubMed ID: 30586199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial.
    Kanniess F; Scuri M; Vezzoli S; Francisco C; Petruzzelli S
    Pulm Pharmacol Ther; 2015 Feb; 30():121-7. PubMed ID: 25088067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of extrafine beclomethasone dipropionate/formoterol fumarate dry powder inhaler and pressurized metered-dose inhaler in Chinese patients with asthma: the FORTUNE study.
    Zheng J; Zhang J; Fu X; Lin C; Zhang X; Mei X; Corradi M; Cappellini G; Calabro E; Zhu C; Topole E
    J Asthma; 2024 Apr; 61(4):360-367. PubMed ID: 37878325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial.
    Beeh KM; Kuna P; Corradi M; Viaud I; Guasconi A; Georges G
    Int J Chron Obstruct Pulmon Dis; 2021; 16():79-89. PubMed ID: 33488071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study.
    Singh D; Ciurlia G; Piccinno A; Muraro A; Bocchi M; Scuri M
    Pulm Pharmacol Ther; 2017 Feb; 42():43-51. PubMed ID: 28065679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma.
    Kuna P; Govoni M; Lucci G; Scuri M; Acerbi D; Stelmach I
    Br J Clin Pharmacol; 2015 Sep; 80(3):569-80. PubMed ID: 25808292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids.
    Paggiaro P; Corradi M; Latorre M; Raptis H; Muraro A; Gessner C; Siergiejko Z; Scuri M; Petruzzelli S
    BMC Pulm Med; 2016 Dec; 16(1):180. PubMed ID: 27938358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relief of methacholine-induced bronchospasm with extrafine beclomethasone dipropionate/formoterol in comparison with salbutamol in asthma.
    Singh D; Corradi M; Bindi E; Baronio R; Petruzzelli S; Paggiaro P
    Pulm Pharmacol Ther; 2012 Oct; 25(5):392-8. PubMed ID: 22842339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler
    Virchow JC; Poli G; Herpich C; Kietzig C; Ehlich H; Braeutigam D; Sommerer K; Häussermann S; Mariotti F
    J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):269-280. PubMed ID: 29989511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma.
    Crisafulli E; Zanini A; Pisi G; Pignatti P; Poli G; Scuri M; Chetta A
    Expert Rev Respir Med; 2016; 10(5):481-90. PubMed ID: 26938578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers.
    Luo Z; Lucci G; Santoro L; Topole E; Mariotti F
    Pulm Pharmacol Ther; 2022 Jun; 73-74():102129. PubMed ID: 35525480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bronchodilating effects of a new beclometasone dipropionate plus formoterol fumarate formulation via pressurized metered-dose inhaler in asthmatic children: a double-blind, randomized, cross-over clinical study.
    Pohunek P; Varoli G; Reznichenko Y; Mokia-Serbina S; Brzostek J; Kostromina V; Kaladze M; Muraro A; Carzana E; Armani S; Kaczmarek J
    Eur J Pediatr; 2021 May; 180(5):1467-1475. PubMed ID: 33404895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
    Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
    Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid effects of extrafine beclomethasone dipropionate/formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial.
    O'Connor BJ; Collarini S; Poli G; Brindicci C; Spinola M; Acerbi D; Barnes PJ; Leaker B
    BMC Pulm Med; 2011 Dec; 11():60. PubMed ID: 22188731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of beclometasone dipropionate/formoterol extra-fine fixed combination on the peripheral airway inflammation in controlled asthma.
    Bulac S; Cimrin A; Ellidokuz H
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):82-7. PubMed ID: 25050594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
    Zheng J; Baldi S; Zhao L; Li H; Lee KH; Singh D; Papi A; Grapin F; Guasconi A; Georges G
    Respir Res; 2021 Mar; 22(1):90. PubMed ID: 33757520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment response according to small airways disease status: The effects of high-strength extrafine pMDI beclomethasone dipropionate/formoterol fumarate in fixed dose combination in moderate uncontrolled asthmatic patients.
    Carpagnano GE; Scioscia G; Lacedonia D; Stornelli SR; Irene Quarato CM; Soccio P; Resta O; Foschino Barbaro MP
    Pulm Pharmacol Ther; 2020 Feb; 60():101879. PubMed ID: 31866498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of extrafine formulation of BDP/FF inhaler on asthma control, small airway function and airway inflammation among Mexican asthmatic patients. A retrospective analysis.
    Díaz-García R; Flores-Ramírez G; Ramírez-Oseguera RT
    Respir Med; 2020; 165():105932. PubMed ID: 32308205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation.
    Müller V; Gálffy G; Eszes N; Losonczy G; Bizzi A; Nicolini G; Chrystyn H; Tamási L
    BMC Pulm Med; 2011 Jul; 11():40. PubMed ID: 21762500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An innovative corticosteroid/long-acting β
    Usmani O; Roche N; Marshall J; Danagher H; Price D
    Expert Opin Drug Deliv; 2019 Dec; 16(12):1367-1380. PubMed ID: 31752560
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.